Whistleblower: Abbott off-label TriCor scheme put patients at risk
This article was originally published in Scrip
Executive Summary
Abbott "trained, directed, incentivized and encouraged" its sales representatives to market TriCor (fenofibrate) for unapproved uses and to "misrepresent and withhold clinical information" about the medicine's known risks and its efficacy, a former employee is charging in a whistleblower lawsuit brought against the firm, which has been joined by the federal government and 22 states and the District of Columbia.